Outlook Therapeutics (OTLK) Requests Type A FDA Meeting Following CRL

Outlook Therapeutics (OTLK) has submitted a Type A meeting request to the U.S. Food and Drug Administration following receipt of a Complete Response Letter (CRL) on February 7, 2026. The company plans to discuss the CRL and address data or procedural issues that require clarification to advance its drug development program. The CRL relates to the company's lead therapy, a first-in-class treatment for solid tumors, and the meeting is scheduled for March 15, 2026. The outcome of the meeting will determine the next steps in the regulatory process.